Harvard Bioscience director awarded 16,556 RSUs
Eade Katherine A. reported acquisition or exercise transactions in this Form 4 filing.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Eade Katherine A. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Katherine A. Eade received an award of 16,556 restricted stock units of common stock at no cost. The RSUs vest in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first. After this grant, she beneficially owns 58,669 shares, including 42,113 shares of common stock adjusted for a 10-for-1 reverse stock split that took effect on March 13, 2026.
Insider Trade Summary
Grant/Award: 16,556 shares
Grant/Award
1 txn
Insider
Eade Katherine A.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16,556 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 58,669 shares (Direct)
Holdings Before and After:
Common Stock, 42,113 to 58,669 shares (Direct)
Footnotes (3)
- F1. Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
- F2. Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.
- F3. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Key Figures
RSU award: 16,556 units
Shares after transaction: 58,669 shares
Previously owned common stock: 42,113 shares
+3 more
6 metrics
RSU award
16,556 units
Restricted stock units granted to director Katherine A. Eade
Shares after transaction
58,669 shares
Total beneficial ownership following RSU grant
Previously owned common stock
42,113 shares
Beneficially owned common shares included in post-grant total
Reverse stock split ratio
10-for-1
Common stock reverse split effective March 13, 2026
Pre-split RSUs reported
110,000 units
Previously reported restricted stock units before 10-for-1 split
Pre-split common shares
311,126 shares
Previously beneficially owned common stock before split adjustment
Key Terms
restricted stock units, reverse stock split, beneficially owned, annual meeting
4 terms
restricted stock units financial
"Represents an award of 16,556 restricted stock units that vests in full"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
reverse stock split financial
"underwent a reverse stock split in a ratio of 10-for-1"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
beneficially owned financial
"42,113 shares of common stock beneficially owned by the Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
annual meeting financial
"vests in full (i) immediately prior to the Company's next annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Harvard Bioscience (HBIO) report for Katherine A. Eade?
Harvard Bioscience reported a stock-based compensation grant to director Katherine A. Eade. She received 16,556 restricted stock units of common stock, increasing her beneficial ownership to 58,669 shares following the award, according to the Form 4 filing details and accompanying footnotes.
How many restricted stock units did the Harvard Bioscience director receive?
Director Katherine A. Eade received an award of 16,556 restricted stock units. These RSUs represent a stock-based compensation grant and will convert into shares of common stock upon vesting under the specified schedule, without any cash purchase price per unit reported in the filing.
What are the vesting terms of Katherine A. Eade’s 16,556 RSUs at Harvard Bioscience (HBIO)?
The 16,556 restricted stock units vest in full on the earlier of two dates. They vest immediately prior to Harvard Bioscience’s next annual meeting, or one year from the grant date, whichever occurs first, providing a single cliff-vesting schedule for this director equity award.
How did Harvard Bioscience’s March 13, 2026 reverse stock split affect the director’s reported holdings?
Harvard Bioscience completed a 10-for-1 reverse stock split on March 13, 2026. After this split, previously reported holdings of 110,000 restricted stock units and 311,126 common shares were adjusted to 42,113 shares of common stock, which now form part of Katherine A. Eade’s 58,669 total shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
